Skip to main content
SpringerLink
Log in

A recombinant single-chain antibody interleukin-2 fusion protein

  • Published:
Cell Biophysics Aims and scope Submit manuscript

Abstract

Recombinant interleukin-2 (rIL-2) therapy has been shown to be of value in the treatment of some cases of melanoma and renal cell carcinoma. However, its use can be limited by severe systemic toxicity. Targeting rIL-2 to the tumor should improve the antitumor immune response and decrease the systemic toxicity. With this aim, we have employed recombinant DNA techniques to construct a single-chain antibody interleukin-2 fusion protein (SCA-IL-2).

The protein used in this model system consists of the variable domains of the antilysozyme antibody D1.3 fused to human IL-2 and is expressed inE. coli. It retains antigen-binding specificity and has the full biological activity of rIL-2.

This approach can be taken to generate SCA-IL-2 proteins that bind to appropriate cellular antigens. In vivo administration of tumor-binding SCA-IL-2 should result in a localized high concentration of rIL-2 in the tumor tissues, maximizing the antitumor response while keeping systemic side effects to a minimum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

rIL-2:

recombinant interleukin-2

SCA:

single-chain antibody

SCA-IL-2:

single-chain antibody interleukin-2 fusion protein

References

  1. Gillis, S., Ferm, M. M., Ou, W., and Smith, K. A. (1978) T cell growth factor: parameters of production and a quantitative microassay for activity.J. Immunol. 120, 2027–2032.

    PubMed  CAS  Google Scholar 

  2. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A., and White, D. E. (1989) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients.Ann. Surg. 210, 474–485.

    Article  PubMed  CAS  Google Scholar 

  3. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.Cell 60, 397–403.

    Article  PubMed  CAS  Google Scholar 

  4. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Gebauffe, F., Strom, T. B., and Murphy, J. R. (1987) Diptheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diptheria toxin-related interleukin-2 fusion protein.Prot. Engin. 1, 493–498.

    Article  CAS  Google Scholar 

  5. Kiyokawa, T., Williams, D. P., Snider, C. E., Strom, T. B., and Murphy J. R. (1991) Protein engineering of diptheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high affinity IL-2-receptor bearing target cells.Prot. Engin. 4, 463–468.

    Article  CAS  Google Scholar 

  6. Lorderboum-Galski, H., Fitzgerald, D., Chaudary, V., Aldhaya, S., and Pastan, I. (1988) Cytotoxic activity of an interleukin-2-Pseudomonas exotoxin chimeric protein produced inEscherichia coli.Proc. Natl. Acad. Sci. USA 85, 1922–1926.

    Article  Google Scholar 

  7. Landolf, N. F. (1991) A chimeric IL-2/Ig molecule possesses the functional activity of both proteins.J. Immunol. 146, 915–919.

    Google Scholar 

  8. Fell, H. P., Gayle, M. A., Grosmaire, L., and Ledbetter, J. A. (1991) Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab’) with specificity for carcinomas and human IL-2.J. Immunol. 146, 2446–2452.

    PubMed  CAS  Google Scholar 

  9. Houston, J. S., Levinson D., Mudgett-Hunter, M., Tai, M.-S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., Crea, R., and Opperman, H. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv anlogue produced inEscherichia coli.Proc. Natl. Acad. Sci. USA 85, 5879–5883.

    Article  Google Scholar 

  10. Colcher, D., Bird, R., Roselli, M., Hardman, K. D., Johnson, S., Pope, S., Dodd, S., Pantoliano, M. W., Milenic, D. E., and Schlom, J. (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein.JNCI 82, 1191–1197.

    Article  PubMed  CAS  Google Scholar 

  11. Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. (1991) Making antibody fragments using phage display libraries.Nature 352, 624–628.

    Article  PubMed  CAS  Google Scholar 

  12. Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffith, D., and Winter, G. (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage.J. Mol. Biol. 222, 581–597.

    Article  PubMed  CAS  Google Scholar 

  13. McCafferty, J., Griffiths, A. D., Winter, G., and Chiswell, D. J. (1990) Phage antibodies: filamentous phage displaying antibody variable domains.Nature 348, 552–554.

    Article  PubMed  CAS  Google Scholar 

  14. Stauch, K. L., Johnson, K., and Beckwith, J. (1989) Characterization of degP; a gene required for proteolysis in the cell envelope and essential for growth ofEscherichia coli at high temperature,J. Bact. 171, 2689–2696.

    Google Scholar 

  15. Ward, E. S., Gussow, D., Griffiths, A. D., Jones, P. T., and Winter, G. (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted fromEscherichia coli.Nature 341, 544–546.

    Article  PubMed  CAS  Google Scholar 

  16. Smith, K. A., Favata, M. F., and Oroszlan, S. (1983) Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics.J. Immunol. 131, 1808–1815.

    PubMed  CAS  Google Scholar 

  17. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature 227, 680–685.

    Article  PubMed  CAS  Google Scholar 

  18. Towbin, H., Staehelin, T., and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets; procedure and some applications.Proc. Natl. Acad. Sci. USA 76, 4350–4354.

    Article  PubMed  CAS  Google Scholar 

  19. Gillis, S. and Smith, K. A. (1977) Long term culture of tumour-specific cytotoxic T cells.Nature 268, 154–156.

    Article  PubMed  CAS  Google Scholar 

  20. Lei, S. P., Lin, H. C., Wang S. S., Callaway, J., and Wilcox, G. (1987) Characterization of the Erwinia carotova pelB gene and its product pectate lyase.J. Bact. 169, 4379–4383.

    PubMed  CAS  Google Scholar 

  21. Savage, P. M., Beynon, H. C., Hartourian, R., Walport, M. J., and Epenetos, A. A. (1992) A single chain antibody interleukin-2 fusion protein mimics the effects of rIL-2 on endothelial cell permeability, inCell Adhesion Molecules in Cancer and Inflammation (Epenetos, A. A., ed.), Chapman and Hall, London.

    Google Scholar 

  22. Lotze, M. T., Chang, A. G., Seipp, C. A., Simpson, C., Vetto, J. T., and Rosenberg, S. A. (1986) High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer.JAMA 256, 3117–3124.

    Article  PubMed  CAS  Google Scholar 

  23. LeBerthon, B., Khawli, L. A., Alauddin, M., Miller, G. K., Charak, B. S., Mazumder, A., and Epstein, A. L. (1991) Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin-2 immunoconjugate.Cancer Res. 51, 2694–2698.

    PubMed  CAS  Google Scholar 

  24. Hennigan, T. W., Begent, R. H. J., and Allen-Mersh, T. G. (1991) Histamine, leukotriene C4 and interleukin-2 increase antibody uptake into a human carcinoma xenograft model.Br. J. Cancer 64, 872–874.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ICRF Monoclonal Targeting Group, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, W12 OHS, London

    Philip Savage, Robert A. Spooner & Agamemnon A. Epenetos

  2. Department of Rheumatology, Royal Postgraduate Medical School, Hammersmith Hospital, W12 OHS, London

    Philip Savage & Alex So

Authors
  1. Philip Savage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex So
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. Spooner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Agamemnon A. Epenetos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savage, P., So, A., Spooner, R.A. et al. A recombinant single-chain antibody interleukin-2 fusion protein. Cell Biophysics 22, 61–77 (1993). https://doi.org/10.1007/BF03033867

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03033867

Index Entries

Search

Navigation